Medtronic’s Extravascular ICD Stops Ventricular Arrhythmias In Pilot Trial

In a 21-patient first in-human pilot trial, Medtronic’s Extravascular Implantable Cardioverter Defibrillator (EV ICD) system successfully terminated induced ventricular arrhythmias in 89.5% of patients and achieved pacing capture in 95% of patients.

FRIDLEY, MN/USA - JUNE 23, 2014: Medtronic corporate headquarters campus. Medtronicis the world's fourth largest medical device company and is a Fortune 500 company. - Image
• Source: shutterstock.com

More from Clinical Trials

More from R&D